Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing <i>tumour protein 53</i> gene status.

Furthermore, following the 1 μmol/L treatment of the NSCLC cell pair ( Figure 3A and Figure 3B ), there is clearly a greater loss of proliferation noted for the TP53 MUT cell H23 ( Figure 3B ) upon treatment, compared to the TP53 WT cell A549 ( Figure 3A ); the decrease in cell growth being highly significant at days 3–4 for the H23 cells, compared the growth of the untreated cells.

also in 132,142 other papers